Avacta Group在ESMO大会上为AVA6000癌症治疗提供了前景良好的第一阶段临床数据。 Avacta Group presents promising Phase 1 clinical data for AVA6000 cancer treatment at ESMO Congress.

在ESMO大会上,Avacta集团提供了AVA6000的最新的第一期临床数据,显示了固体瘤患者的多次持续和持久反应. Avacta Group presented updated Phase 1 clinical data for AVA6000 at the ESMO Congress, revealing multiple ongoing and durable responses in patients with solid tumors. 这项宣布凸显了AVA6000作为肿瘤学有希望的治疗方案的潜力,反映了该公司在癌症治疗方面的进步。 This announcement highlights the potential of AVA6000 as a promising treatment option in oncology, reflecting the company’s advancements in cancer therapies. 研究结果可为这一领域的临床进一步发展和研究铺平道路。 The results may pave the way for further clinical development and research in this area.